Cointime

Syndesi Therapeutics

company

About

Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions.

  • 11 - 50

Highlights

Total Funding Amount
€3.20M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Grant
Last Funding Money Raised
€3.20M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2018
Number Of Employee
11 - 50
Operating Status
Active

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€3.20M
Syndesi Therapeutics has raised a total of €3.20M in funding over 2 rounds. Their latest funding was raised on Mar 20, 2019 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 20, 2019 Grant €3.20M 1 W.IN.G — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Syndesi Therapeutics is funded by 1 investors. W.IN.G are the most recent investors.
Investor Name Lead Investor Funding Round
W.IN.G Yes Grant
Cointime
Content
Company